chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It is swollen up; inflamation; arm started hurting; My entire arm hurts, from my fingers to my shoulder; I am in tremendous pain; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PERIPHERAL SWELLING (It is swollen up), INFLAMMATION (inflamation), PAIN IN EXTREMITY (My entire arm hurts, from my fingers to my shoulder), PAIN (I am in tremendous pain) and PAIN IN EXTREMITY (arm started hurting) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, the patient experienced PAIN IN EXTREMITY (My entire arm hurts, from my fingers to my shoulder) and PAIN (I am in tremendous pain). On an unknown date, the patient experienced PERIPHERAL SWELLING (It is swollen up), INFLAMMATION (inflamation) and PAIN IN EXTREMITY (arm started hurting). At the time of the report, PERIPHERAL SWELLING (It is swollen up), INFLAMMATION (inflamation), PAIN IN EXTREMITY (My entire arm hurts, from my fingers to my shoulder), PAIN (I am in tremendous pain) and PAIN IN EXTREMITY (arm started hurting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product details provided.  Patient went to the hospital for the reported events. No Treatment information for the event was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 25-Feb-2021 and was forwarded to Moderna on 25-Feb-2021.    This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PERIPHERAL SWELLING (It is swollen up), INFLAMMATION (inflamation), PAIN IN EXTREMITY (My entire arm hurts, from my fingers to my shoulder), PAIN (I am in tremendous pain) and PAIN IN EXTREMITY (arm started hurting) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, the patient experienced PAIN IN EXTREMITY (My entire arm hurts, from my fingers to my shoulder) and PAIN (I am in tremendous pain). On an unknown date, the patient experienced PERIPHERAL SWELLING (It is swollen up), INFLAMMATION (inflamation) and PAIN IN EXTREMITY (arm started hurting). At the time of the report, PERIPHERAL SWELLING (It is swollen up), INFLAMMATION (inflamation), PAIN IN EXTREMITY (My entire arm hurts, from my fingers to my shoulder), PAIN (I am in tremendous pain) and PAIN IN EXTREMITY (arm started hurting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product details provided.  Patient went to the hospital for the reported events. No Treatment information for the event was provided.
Moderate to severe myalgias, arthralgias, & headache (HA) started 1/21/21 ~16hrs after 2nd vaccine dose. (Had mild-mod HA after 1st dose 12/30/20 which resolved after ~10days, with persistent neck/facial flushing & chills that decreased in frequency). Myalgias & arthralgias resolved ~4 - 5 days later, flushing/chills & HA continued, though severity lessened. Attempted return to work Wed 1/27 but severe HA w nausea began while driving. HA continued but decreased to mild ~1/31, and returned to work Wed 2/3 (reg sched is Wed-Fri, 3 x 12.5hrs). Mid morning Thurs 2/4 at work severe HA & nausea returned, had to leave work. Mod-sev HA continues 2/9/21, 20days after vaccine #2, and not cleared to return to work.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided.  It was reported that there were no power outages, but the facility was not able to download digital data logger. The data logger was unable to download the data for Dec-2021, Jan-2022 and Feb-2022 No treatment medication information was given.
No adverse effects reported; patient received improperly stored dose of vaccine; This spontaneous report was received from a nurse referring to a 4 years old patient of unknown gender. Information about concurrent condition, concomitant medication or medical history was not provided.   On 23-SEP-2019, the patient was vaccinated with improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # S009756, expiration date 27-SEP-2020; vaccine dosage detail  and route were not reported) for prophylaxis, which was reconstituted with properly stored sterile diluent product storage error). Current temperature excursion was -14 Celsius degrees to -10 Celsius degrees (-13 Celsius degrees) for 3 days. There was no previous temperature excursion. No adverse effects were reported. Data logger was involved.
The patient notified nurse staff she was lightheaded and shortness of breath. Patient vitals were taken by nurse:  Respiratory: 24 Pulse: 60 Temperature: 96.9 BP: 108/60 Alter orient x1 -EMS was called to respond. They provided the patient with additional fluids and was cleared to go without transport to the hospital.
Narrative: COVID infection following COVID vaccine series 02/11, Pfizer, dose#1 03/04, Pfizer, dose #2 07/23 COVID swab, result: NOT detected 08/26 pt cc: cough, loss of taste or smell, fever, exposure: unknown 09/02 COVID swab, result: detected 09/02 SARS-COV-2 LINEAGE result: AY. 4 09/02 SARS-COV-2 CLADE result: 21 J (DELTA)
Severe stiff neck; Can hardly sleep; so sick the day after and slept all day; Neck was sore/neck is still sore, but not severe; Nauseous; so sick the day after and slept all day; can hardly move it; This is a spontaneous report from a contactable consumer (patient). A 68-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 2 via an unspecified route of administration at the age of 68-year-old on 07Apr2021 (Batch/Lot number was not reported) as single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously took first dose bnt162b2 for COVID-19 immunization and after the first dose, she only had a mild headache. She experienced a severe stiff neck after the second dose in Apr2021.  It has been 5 days.  She can hardly move it and can hardly sleep in Apr2021.  She was so sick the day after and slept all day in Apr2021. The next day was better. Then her neck was sore and she got nauseous in Apr2021.  Her neck was still sore, but not severe.  She wants to know if she should wait a whole week and then see her doctor or does she need to see a doctor now. She received the second dose last Wednesday (07Apr2021) and still has symptoms today. The outcome of events was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This is a spontaneous report from a contactable nurse via a sales representative. A patient (age and gender unknown) received a dose of PREVNAR 13 and on unspecified date. Relevant medical history and concomitant medications were unknown. The nurse wanted to know "why does PREVNAR 13 hurt more than the rest?" Outcome was unknown.
I gave patient a Tdap which is not licensed for children his age instead of a Dtap which is what I should have administered.
moderna mistakenly given to a 14 yrs old.   no ill or side effects resulted.
has a feeling of her heart racing or fluttering/her heart beating out of her chest it was a fluttering feeling; has a feeling of her heart racing or fluttering/her heart beating out of her chest it was a fluttering feeling; This is a spontaneous report from a contactable consumer (patient) via medical information team. A 34-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, lot number: unknown) via an unspecified route of administration on 19Aug2021 (age at the time of vaccination was 34 years) as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medication were not reported. Caller stated that she was scheduled to receive the Pfizer COVID vaccine second dose today and she was questioning if she should get the second dose because the same night (19Aug2021) she got the first dose of the vaccine she had a feeling of her heart racing or fluttering. Caller would like to know if we have any recommendations for her regarding receiving the second dose. Caller stated that it was scary that night and you could see her heart beating out of her chest it was a fluttering feeling and that was the best way that she can describe it. The clinical outcome of the events were unknown.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Patient start at night with headache, fever, vomiting and swelling of left arm x 3 days.
Information has been received from an physician concerning a 16 year old male patient with asthma, obesity, allergy to penicillin, amoxicillin, MOTRIN, BENADRYL and shellfish, the patient never had chickenpox. Who on 23-MAY-1997 was vaccinated with the first dose of VARIVAX (Merck) and on 10-OCT-2008 was vaccinated with the second dose of VARIVAX (Merck) (Lot numbers, routes and doses not reported). Concomitant therapy included albuterol and montelukast sodium (MSD). It was reported that on 21-SEP-2011, the patient developed severe gastritis and gastric perforation that required resection on his stomach, due uncontrollable bleeding. The physician stated that because there were several cases of gastritis reported due to varicella zoster virus (VZV) in immunocompromised patients, they looked at the patient's saliva for VZV DNA and found it positive. The patient was so ill afterwards he was transferred to another hospital. It was too late to treat him with an antiviral drug, but he did recovered from the surgery. He was now at home. On 26-OCT-2011, a gastric mucosa sample was obtained from endoscopy biopsy, results not reported. At the time of the report outcome of Severe gastritis, Uncontrollable bleeding and gastric perforation was unknown. Upon internal review gastric perforation and resection of his stomach were considered to be an other important medical events. Additional information has been requested.
chilss; body aches; headache; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chilss), MYALGIA (body aches) and HEADACHE (headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CHILLS (chilss), MYALGIA (body aches) and HEADACHE (headache). At the time of the report, CHILLS (chilss), MYALGIA (body aches) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100.8 High.
A report has been received from a Health Professional concerning, subject of unknown gender, who had been receiving Nasal FLUMIST QUADRIVALENT. FLUMIST QUADRIVALENT started on an unknown date. The patient experienced tested positive for flu (Preferred term: influenza virus test positive). The outcome of the event of tested positive for flu is unknown. The report was considered to be non-serious by the reporter.
Pain in right shoulder, close to the left armpit. Also have inflammation in the armpit area.
Ongoing migraine present for over 48 hours. Nausea, vomiting, back pain, joint pain, neck pain, pain at injection site, fever, chills, fatigue, all lasting for 36 hours.
Hospitalization for general weakness due to COVID-19 on dates 11/28/2022- 12/1/2022. Treated with vitamin C 1,000 mg PO daily, vitamin D 25 mcg PO daily, zinc 50 mg PO daily.
Stated she felt her throat closing up, SOB and anxiety.  Was given 1 injection of epinephrine, declined calling an ambulance and was take to local ER by grandparent.
Dizziness, headaches, unable to focus or concentrate, blurred vision when viewing computer screen or video games Unable to concentrate enough to pay bills by check.
pt had vasovagal response, one she woke up she told me she had a history if, She was in a chair when she passed out, we attempted to get her on the ground with feet up but in the process her head bumped the floor (it was not too bad it seemed), paramedics came as i called them when she was unresponsive, they did take her to the hospital i assume for low blood pressure but I am not sure what for (she was awake, i had to walk away for a few minutes and let the paramedics takeover),
CHILLS; FEVER; HEADACHE; This spontaneous report received from a patient concerned a 76 year old female. The patient's weight, height, and medical history were not reported. The patient experienced drug allergy when treated with acetylsalicylic acid for drug used for unknown indication. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1802072, and batch number: 1802072 expiry: UNKNOWN) dose was not reported, administered on 12-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 13-MAR-2021, the subject experienced chills. On 13-MAR-2021, the subject experienced fever. On 13-MAR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from chills, and headache, and had not recovered from fever. This report was non-serious.
pain; fever; soreness on her arm; feels hungry more than normal; A spontaneous report was received from a Consumer concerning a 73-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events pain, fever and soreness on her arm, feels hungry more than normal.  The patient's medical history was not provided. Concomitant medications reported were Losartan 25mg for drug use for unknown indication.  On 3 Feb 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 007m20a) intramuscularly for prophylaxis of COVID-19 infection.  On 3 Feb 2021, the patient experienced the events pain. fever and soreness on her arm, feels hungry more than normal.  Treatment details included Ibuprofen 200mg  Action taken with mRNA-1273 in response to the events was not reported.   On an unknown date the outcome of events, pain, On an unknown date the outcome of events, fever and soreness on her arm, On an unknown date the outcome of events, feels hungry more than normal was not reported.
This spontaneous report as received from a physician refers to a 5 year old female patient. On 25-MAR-2014 the patient was vaccinated with a dose of GARDASIL (route, dose, frequency and lot # were unknown). No adverse effects reported. Additional information has been requested.
Wednesday, woke up at 06:30 with stomach cramps. Threw up. Still had cramps throughout the day but they were mild. Did not throw up again. Have recovered from this.  The next day, 24th, evening about 06:00 pm - rash on hands. It was the same on both hands. It is red with little red marks. Not a bump. It isn't itchy and doesn't hurt at all - it's between index finger and thumb on both of my  hands and it spreads out between the fleshy part between the hand and the knuckle : Thumb, index finger, middle finger and pinky there's a red splotch on each of those parts of both hands. It's exactly the same on both hands. Called Dr on Friday morning. I will watch it to see what it does. No bumps and no discomfort (not dry or itchy). It just stays there (little tiny red spots) - been there for five days.
Head feels heavy, throat tightness & feels dry. Benadryl 25 mg taken po by employee @ 11:05 AM.
Puffy eyes; eye pain in lids. ? 12hrs   Pain in chest. Pain inhaling to take deep breath. Strenuous activity makes chest hurt more.   Pain in  left side of neck. Swollen lymph nodes.
11/2/21 that evening felt fatigued and weak 11/3/21 woke up with a fever, fatigued, weak, and cough 11/4/21 cough, fever, weak, fatigued, lung congestion 11/5/21 cough, fever, weak, fatigued, lung congestion 11/6/21 diagnosed with pneumonia viral and bacterial
Flu shot administered 10/14/2008 at 1:10 PM at clinic. Reaction was queasy at first, within minutes. Ten minutes afterward patient became somewhat dizzy and disoriented, which passed after a few minutes. Felt some cranial pressure for two days. Arm sore for a week after the shot.
1 inch x 1 inch Hard Lump, Warm to touch, Sore for 3 days but beginning to lessen.
The posibility of the administration of one separate dose of an improperly stored vaccine; The posibility of the administration of one separate dose of an improperly stored vaccine; No adverse effect; This spontaneous report was received from a medical assistant and refers to a 4 or 5 years old child of unknown gender. The patients' pertinent concurrent conditions, medical history, concomitant medications and drug reactions or allergies were not provided.   The medical assistant reported, the possibility of the administration an improperly stored dose (product storage error and circumstance or information capable of leading to medication error) of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD)subcutaneously,  lot # R001540 with expiration date on 15-JUL-2019 for prophylaxis (strength, anatomical side of injection and dose # were not provided) to one patient who was approximately 4 or 5 years old on unspecified date. No adverse effect reported nor product quality complain.  In addition, the medical assistant stated that measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD) was reconstituted with properly stored sterile diluent (lot # N006325 with expiration date on 07-AUG-2019).   The dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD) was exposed to a temperature excursion of -13 degrees Celsius (°C)  for 5 hours and a temperature of -13 degrees Celsius (°C) with time frame of 8 hours, which was detected by the Digital Data Logger.
Febrile seizure, patient had a seziure episode <5 minutes, tonic clonic. no medications adminitered. Fever 103.4F on presentation to the ED.
Information has been received from a physician concerning a 25 year old female patient with no pertinent medical history and allergy to meningococcal vaccine (unspecified) and plum's allergy who on 04-OCT-2011, was vaccinated with the first dose of GARDASIL, 0.5 mL, IM (lot # 670048/0963AA, expiration date 09-NOV-2013) and the second dose of GARDASIL, 0.5 mL, IM (lot # 668261/1397AA, expiration date 09-APR-2012) administered on 06-DEC-2011. In December 2011, the patient experienced nausea after receiving the second dose of GARDASIL. On 09-APR-2012, the patient received the third dose of GARDASIL 0.5 mL, IM (lot # 1745AA, expiration date 13-DEC-2014). Concomitant therapy included contraceptive pills (unspecified). On 09-APR-2012 "within 2 hours of administration of the third dose of GARDASIL", the patient experienced foreign body sensation in her throat and nausea. The patient was administered BENADRYL oral, a nebulizer (unspecified) treatment and epinephrine intramuscular, in the physician's office. The patient went to the emergency room and was given prednisone 60 mg oral (dosage was titrated over a few days) and released without admission to the hospital. On 10-APR-2012, the patient went to the physician's office and was found to have puffy upper eyelids as well as persistence of the foreign body sensation in her throat. The patient was given ZYRTEC and prednisone while in the office. No laboratory tests were performed. The patient was continued on ZYRTEC. At the time of the report, the patient continued to experience a foreign body sensation in her throat and the outcome for nausea and puffy upper eyelids was unknown. Upon internal review the use of epinephrine IM was determined to be an other important medical event. Additional information has been requested.
Initial report was retrieved from the scientific literature on 06 September 2012. The following information is verbatim from the abstract: "Meningococci have historically caused extensive illness among members. Three successive meningococcal vaccine types were used from 1971 through 2010; overall disease incidence dropped by >90% during this period. During 2006-2010, disease incidence of 0.38 (cases per 100,000 person-years) among members was not significantly different from the incidence of 0.26 among the age-matched general population. Of the 26 cases, 5 were fatal, 15 were vaccine failures (e.g., illness in a person who had been vaccinated), and 9 were caused by Neisseria meningitidis serogroup Y. Incidences among 17- to 19-year-old were significantly higher than among comparison populations (p<0.05). No apparent change in epidemiology of meningococcal disease was observed after replacement of quadrivalent polysaccharide vaccine with conjugate vaccine in 2007. The data demonstrate that vaccination with meningococcal vaccine is effective." According to the report, the cases were confirmed by culture, PCR or both. The information included in this case concerns a 20-24-year-old male patient who had received MENOMUNE A/C/Y/W-135 (lot number, route, site and date of administration not reported) and an unspecified amount of time after vaccination developed meningococcal meningitis, year reported as 2006 (Q 3). Neisseria meningitidis serogroup for this case was unknown. Treatments were not reported. No further information was available at the time of report. Death was reported as "No", however the patient's outcome was not reported. The reporter for this case is the same as for cases 2012-08240, -08241, -08242, -08243, -08244, -08245, -08246, -08247, -08248, -08249, -08250, -08251, -08252, -08253, -08254 and -08255. Documents held by sender: None.
Hives,  welts, itchy, red skin, dermatographia - symptoms began randomly, appx 2 weeks after receiving vaccine. No prior history of allergies.